Companies: 10,795·Total market cap: $144.5T
Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

AVDLNASDAQHealthcare
$21.64
+$0.00(+0.00%)
Market Cap$2.1B
P/E Ratio
52W High$23.57
52W Low$6.38
Overview

Avadel Pharmaceuticals plc (AVDL) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

avdl · stock forecast · 14 analysts (3M) · FMP · updated Mar 24, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Buy

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
8
Hold
6
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 57.1%

12-Month Price Target

High

$30.00

Consensus

$21.43

-1.0% upside

Low

$18.50

Median: $20 · Last Close: $21.64

The Avadel Pharmaceuticals plc (AVDL) analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month AVDL price target is $21.43, representing -1.0% upside from the current price of $21.64.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $21 (-1.0%)

Consensus Target

$21.43

-1.0% upside

High Target

$30

38.6%

Low Target

$18.5

-14.5%

Current Price

$21.64

as of today

Based on analyst price targets, the AVDL stock price prediction for the next 12 months ranges from $18.5 to $30. The consensus AVDL price forecast of $21.43 implies -1.0% upside from the current price of $21.64.

Short-Term Price Prediction

Ranging

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$21.650.06%

1-day model range: $21.65–$21.66. Peak: $21.66 (+0.06%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$27+24.5%
2028$31+42.9%
2029$34+55.5%
2030$35+63.8%
2031+69.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%7%0%
13Buy
1Neutral
0Sell
RSI (14)61.3Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · AVDL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$21.63BUY
MA 10$21.62BUY
MA 20$21.57BUY
MA 50$21.51BUY
MA 100$19.82BUY
MA 200$15.56BUY
Current $AVDL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$21.63BUY
EMA 10$21.62BUY
EMA 20$21.58BUY
EMA 50$21.18BUY
EMA 100$19.65BUY
EMA 200$17.10BUY
Current $AVDL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2025-11-20
Maintains
Equal WeightEqual Weight
Wells Fargo2025-11-07
Maintains
Equal WeightEqual Weight
UBS2025-10-28
Downgrade ↓
BuyNeutral
HC Wainwright & Co.2025-10-23
Downgrade ↓
BuyNeutral
Leerink Partners2025-10-23
Downgrade ↓
OutperformMarket Perform
Jefferies2025-10-22
Downgrade ↓
BuyHold
Needham2025-10-22
Downgrade ↓
BuyHold
HC Wainwright & Co.2025-09-05
Maintains
BuyBuy
UBS2025-08-21
Maintains
BuyBuy
HC Wainwright & Co.2025-08-08
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Avadel Pharmaceuticals plc (AVDL) stock. Of the recent 77 rating actions, 2 were upgrades and 8 were downgrades. 14 analysts currently cover AVDL.

Analyst Recommendation Trends

Buy ratings101
Hold ratings02↑ +2
Sell ratings00

AVDL analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$277M

↓ 35.1% YoY

Revenue Next Year

$356M

↑ 28.2% YoY

EPS This Year

$0.13

EPS Next Year

$0.77

↑ 507.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast AVDL EPS of $0.13 for the current fiscal year, based on estimates from 6 analysts. The AVDL revenue forecast is $277M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The AVDL stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AVDL price target is $21.43 (-1.0% upside), with an analyst consensus of Buy.

The AVDL short-term stock prediction for tomorrow is $21.65 (+0.06%). The AVDL stock price prediction for 2027 estimates an average of $27. The AVDL stock prediction for 2030 projects a range of $35–$36.

Avadel Pharmaceuticals plc trades on NASDAQ under the ticker AVDL. The AVDL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

AVDL forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month AVDL price target is $21.43, with a high forecast of $30.00 and a low of $18.50. The median price target is shown in the chart above when available. This implies -1.0% potential upside from the current price of $21.64.

AVDL price targetWhat is AVDL price targetAVDL analyst price targetAVDL 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.